| Dr James Urbanski, | |
|
1704 W 1st St, Cedar Falls, IA 50613-1841 | |
| (319) 246-5510 | |
| (319) 235-5360 |
| Full Name | Dr James Urbanski |
|---|---|
| Gender | Male |
| Speciality | Audiologist-hearing Aid Fitter |
| Location | 1704 W 1st St, Cedar Falls, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548782287 | NPI | - | NPPES |
| IB1795010 | Other | IA | MEDICARE |
| Provider Name | Northland Hearing Centers Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1225070667 PECOS PAC ID: 3072514884 Enrollment ID: O20100803000403 |
News Archive
New research led by UC Davis scientists provides insight into why some body organs are more susceptible to cell death than others and could eventually lead to advances in treating or preventing heart attack or stroke.
Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.
Nearly 650,000 people are released from state and federal prison yearly and arrive on the doorsteps of communities nationwide. A far greater number reenter communities from local jails.
NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that GATTEX, a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure patients.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Urbanski, 6700 Washington Ave S, Eden Prairie, MN 55344-3405 Ph: (800) 328-8602 | Dr James Urbanski, 1704 W 1st St, Cedar Falls, IA 50613-1841 Ph: (319) 246-5510 |
News Archive
New research led by UC Davis scientists provides insight into why some body organs are more susceptible to cell death than others and could eventually lead to advances in treating or preventing heart attack or stroke.
Biodesix, Inc., a company developing and commercializing molecular diagnostics for personalized medicine, announced today that the United States Patent and Trademark Office has awarded to the Company patent number 7,736,905. The patent provides coverage for the Company's first product, VeriStrat®, which is used by physicians to help guide therapy for patients with advanced lung cancer. The allowed claims are directed towards the serum-based identification of patients likely to benefit from epidermal growth factor targeted therapy.
Nearly 650,000 people are released from state and federal prison yearly and arrive on the doorsteps of communities nationwide. A far greater number reenter communities from local jails.
NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that GATTEX, a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure patients.
› Verified 6 days ago